Vibration perception threshold - A valuable assessment of neural dysfunction in people with diabetes

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 5, 2006, Pages 411-419

  Garrow, Adam P ^a   Boulton, Andrew J M ^b,c  

^a WITHINGTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Diabetes; Neuropathy; Perception; Screening; Vibration

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; ALPHA TOCOPHEROL; ANTIOXIDANT; BERAPROST; CILOSTAZOL; LINOLENIC ACID; PLACEBO; RUBOXISTAURIN; THIOCTIC ACID;

AMPLITUDE MODULATION; ANALGESIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DRUG EFFICACY; EARLY DIAGNOSIS; FOOT AMPUTATION; FOOT CARE; FOOT ULCER; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; INCIDENCE; MORTALITY; NON INVASIVE PROCEDURE; NONHUMAN; PATHOGENESIS; PATIENT EDUCATION; PERCEPTIVE THRESHOLD; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUANTITATIVE ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIBRATION SENSE;

DIABETIC NEPHROPATHIES; HUMANS; PERCEPTION; QUALITY OF LIFE; SENSORY THRESHOLDS; VIBRATION;

EID: 33749018218     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.657     Document Type: Article

References (57)

1. American Diabetes Association, American Academy of Neurology. Consensus statement: report and recommendations of the San Antonio conference on diabetic neuropathy. Diabetes Care 1988; 11: 592-597.
2. Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486.
3. Vileikyte L, Peyrot M, Bundy C, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care 2003; 26: 2549-2555.
4. Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower extremity ulcers in patients with diabetes from two settings. Diabetes Care 1999; 22: 157-162.
5. Boulton AJM, Vinik AI, Arezzo J, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28: 956-962.
6. Coppini DV, Wellmer A, Weng C, et al. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 2001; 8: 520-524.
7. Young MJ, Boulton AJM, Macleod AF, et al. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154.
8. Abbott CA, Carrington AL, Ashe H, et al. The North-West diabetes foot care study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19: 377-384.
9. Valk GD, Grootenhuis PA, Van Eijk JTM, et al. Methods for assessing diabetic polyneuropathy: validity and reproducibility of the measurement of sensory symptom severity and nerve function tests. Diabetes Res Clin Pract 2000; 47: 87-95.
10. Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48-55.
11. Abbott CA, Vileikyte L, Williamson S, et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-1075.
12. Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration. Diabetes Care 2000; 23: 606-611.
13. Krentz AJ, Acheson A, Basu A, et al. Morbidity and mortality associated with diabetic foot disease: a 12-month prospective survey of hospital admissions in a single UK centre. The Foot 1997; 7: 144-147.
14. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387.
15. Ollendorf DA, Kotsanos JG, Wishner WJ, et al. Potential economic benefits of lower extremity amputation prevention strategies in diabetes. Diabetes Care 1998; 21: 1240-1245.
16. Carrington AL, Abbott CA, Griffiths J, et al. A foot care program for diabetic unilateral lower-limb amputees. Diabetes Care 2001; 24: 216-221.
17. Tennvall GR, Apelqvist J. Health-economic consequences of diabetic foot lesions. Clin Infect Dis 2004; 39(Suppl. 2): S132-S139.
18. Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med 1998; 15: 508-514.
19. Arezzo JC. New developments in the diagnosis of diabetic neuropathy. Am J Med 1999; 107(Suppl. 2B): 9S-16S.
20. Perkins BA, Olaleye D, Zinman B, et al. Simple screening tests for peripheral neuropathy in the diabetes clinic. Diabetes Care 2001; 24: 250-256.
21. Dyck PJ, O'Brien PC, Litchy WJ, et al. Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy. Diabetes Care 2005; 28: 2192-2200.
22. Malik RA, Tesfaye S, Newrick PG, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005; 48: 578-585.
23. Armstrong DG, Lavery LA, Vela SA, et al. Choosing a practical screening instrument to identify patients at risk for diabetic foot ulceration. Arch Intern Med 1998; 158: 289-292.
24. Siao P, Cros DP. Quantitative sensory testing. Phys Med Rehabil Clin N Am 2003; 14: 261-286.
25. Williamson RT. The vibration sensation in affections of the nervous system and in diabetes. Lancet 1905; 1: 855-856.
26. Steiness IB. Vibratory perceptions in diabetics: a biothesiometric study. Acta Med Scand 1957; 158: 327-335.
27. Van Deursen RWM, Sanchez MM, Derr JA, et al. Vibration perception threshold testing in patients with diabetic neuropathy: ceiling effects and reliability. Diabet Med 2001; 18: 469-475.
28. Bril V, Kojic J, Ngo M, Clark K. Comparison of a neurothesiometer and vibratron in measuring vibration perception thresholds and relationship to nerve conduction studies. Diabetes Care 1997; 20: 1360-1362.
29. Shy ME, Frohman EM, So YT, et al. Quantitative sensory testing: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2003; 60: 898-904.
30. Young MJ, Breddy JL, Veves A, et al. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. Diabetes Care 1994, 17: 557-560.
31. Wiles PG, Pearce SM, Rice PJS, et al. Vibration perception threshold: influence of age, height, sex, and smoking, and calculation of accurate centile values. Diabet Med 1991; 8: 157-161.
32. Olaleye D, Perkins BA, Bril V. Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic. Diabetes Res Clin Pract 2001; 54: 115-128.
33. Coppini DV, Weng C, Young PJ, et al. The 'VPTscore'- a useful predictor of neuropathy in diabetic patients [letter]. Diabet Med 2000; 17: 488-490.
34. Gin H, Rigalleau V, Baillet L, et al. Comparison between monofilament, tuning fork, and vibration perception tests for screening patients at risk of foot complication. Diabetes Metab (Paris) 2002; 28: 457-461.
35. Dimitrakoudis D, Bril V. Comparison of sensory testing on different toe surfaces: implications for neuropathy screening. Neurology 2002; 59: 611-613.
36. Miranda-Palma B, Sosenko JM, Bowker JH, et al. A comparison of the monofilament with other testing modalities for foot ulcer susceptibility. Diabetes Res Clin Pract 2005; 70: 8-12.
37. Thivolet C, El Farkh J, Petiot A, et al. Measuring vibration sensations with graduated tuning fork. Diabetes Care 1990; 13: 1077-1080.
38. Liniger C, Albeanu A, Bloise D, et al. The tuning fork revisited. Diabet Med 1990; 7: 859-864.
39. Kästenbauer T, Sauseng S, Brath H, et al. The value of the rydelseiffer tuning fork as a predictor of diabetic polyneuropathy compared with a neurothesiometer. Diabet Med 2004; 21: 563-567.
40. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005; 64: 199-207.
41. Boulton AJM, Kubrusly DB, Bowker HJ, et al. Impaired vibratory perception and diabetic foot ulceration. Diabet Med 1986; 3: 335-337.
42. Maser RE, Nielsen VK, Bass EB, et al. Measuring diabetic neuropathy: assessment and comparison of clinical examination and quantitative sensory testing. Diabetes Care 1989; 12: 270-275.
43. Lavery LA, Armstrong DG, Vela SA, et al. Practical criteria for screening patients at high risk for diabetic foot ulceration. Arch Intern Med 1998; 158: 157-162.
44. Frykberg RG, Lavery LA, Pham H, et al. Role of neuropathy and high foot pressures in diabetic foot ulceration. Diabetes Care 1998; 21: 1714-1719.
45. Coppini DV, Bowtell PA, Weng C, et al. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-523.
46. Coppini DV, Young PJ, Weng C, et al. Outcome on diabetic foot complications in relation to clinical examination and quantitative sensory testing: a case-control study. Diabet Med 1998; 15: 765-771.
47. Kästenbauer T, Sauseng S, Sokol G, et al. A prospective study of predictors for foot ulceration in type 2 diabetes. J Am Podiatr Med Assoc 2001; 91: 343-350.
48. Shearer A, Scuffham P, Gordois A, et al. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the US. Diabetes Care 2003; 26: 2305-2310.
49. Cameron NE, Cotter MA. Effects of protein kinase C-inhibition on neurovascular dysfunction in diabetic rats: interaction with oxidative stress and essential fatty acid dysmetabolism. Diabetes Metab Res Rev 2002; 18: 315-323.
50. Kim H, Sasaki T, Maeda K, et al. Protein kinase Cbeta selective inhibitor LY333531 attenuates diabetic hyperalgesia through ameliorating cGMP level of dorsal root ganglion neurons. Diabetes 2003; 52: 2102-2109.
51. Vinik A, Bril V, Kepler P, et al, MBBQ Study Group. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005; 27: 1164-1180.
52. Hamada Y, Nakamura J. Clinical potential of aldose reductase inhibitors in diabetic neuropathy. Treat Endocrinol 2004; 3: 245-255.
53. Van Dam PS. Oxidative stress and diabetic neuropathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2002; 18: 176-184.
54. Tütüncü NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with vitamin E supplementation in type 2 diabetes: a preliminary study. Diabetes Care 1998; 21: 1915-1918.
55. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947-999.
56. Hossain P, Sachdev A, Malik R. Early detection of diabetic peripheral neuropathy with corneal confocal microscopy. Lancet 2005; 366: 1340-1343.
57. Chilton L, Middlemas A, Gardiner N, et al. The p75 neurotrophin receptor appears in plasma in diabetic rats - characterisation of a potential early test for neuropathy. Diabetologia 2004; 47: 1924-1930.